EcoDrugPlus

Proteasome 26s Subunit, Atpase 6

Ensembl ID : ENSAOCG00000015867
Gene Symbol: PSMC6
3 Cross references
241 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 1

Ensembl ID : ENSAOCG00000007350
Gene Symbol: PSMD1
3 Cross references
215 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 11

Ensembl ID : ENSAOCG00000017105
Gene Symbol: PSMD11
4 Cross references
198 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 12

Ensembl ID : ENSAOCG00000018188
Gene Symbol: PSMD12
3 Cross references
222 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 13

Ensembl ID : ENSAOCG00000005512
Gene Symbol: PSMD13
3 Cross references
218 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 14

Ensembl ID : ENSAOCG00000010111
Gene Symbol: PSMD14
3 Cross references
215 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 2

Ensembl ID : ENSAOCG00000005063
Gene Symbol: PSMD2
3 Cross references
224 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 6

Ensembl ID : ENSAOCG00000006886
Gene Symbol: PSMD6
3 Cross references
213 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 7

Ensembl ID : ENSAOCG00000012849
Gene Symbol: PSMD7
3 Cross references
236 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 8

Ensembl ID : ENSAOCG00000006374
Gene Symbol: PSMD8
3 Cross references
213 Possible Orthologues:

Proteasome Subunit Alpha Type-4-Like

Ensembl ID : ENSAOCG00000006404
Gene Symbol: LOC111583743
3 Cross references
199 Possible Orthologues:

Proteasome Subunit Alpha Type-6

Ensembl ID : ENSAOCG00000013135
Gene Symbol: LOC111577552
3 Cross references
262 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).